Anti-tumor medicament based on adenovirus
AssigneeMedizinische Hochschule Hannover
InventorsRita Gerardy-Schahn, Florian Kuehnel, Nikolas Martin, David Schwarzer
Life of this patent
Estimating the term…
Abstract
The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.
Claims16
An adenoviral particle for use in the treatment of a tumour comprising a fusion protein comprising from N-terminus to C-terminus a tail domain of an adenoviral fiber protein which lacks the native knob domain and an amino acid sequence of an endosialidase of bacteriophage origin, wherein the endosialidase lacks its bacteriophage attachment domain, wherein the fusion protein specifically binds to polysialic acid.
Dependencies are inferred from the claim text.